Home Proteases HCV Protease inhibitor Dasabuvir (ABT-333)

research use only

Dasabuvir (ABT-333) HCV Protease inhibitor

Cat.No.S5402

Dasabuvir (ABT-333) is a non-nucleoside inhibitor of NS5B viral RNA-dependent RNA polymerase that inhibits recombinant NS5B polymerases derived from HCV genotype 1a and 1b clinical isolates with IC50 values between 2.2 and 10.7 nM. It is at least 7,000-fold selective for the inhibition of HCV genotype 1 polymerases over human/mammalian polymerases.
Dasabuvir (ABT-333) HCV Protease inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 493.57

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: S540201 DMSO]98 mg/mL]false]Water]Insoluble]false]Ethanol]Insoluble]false Purity: 99.47%
99.47

Chemical Information, Storage & Stability

Molecular Weight 493.57 Formula

C26H27N3O5S

 Storage (From the date of receipt)
CAS No. 1132935-63-7 -- Storage of Stock Solutions

Synonyms N/A Smiles CC(C)(C)C1=CC(=CC(=C1OC)C2=CC3=C(C=C2)C=C(C=C3)NS(=O)(=O)C)N4C=CC(=O)NC4=O

Solubility

In vitro
Batch:

DMSO : 98 mg/mL (198.55 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02534870 Completed
Healthy Volunteer
AbbVie
 September 2015 Phase 1
NCT02734173 Completed
Hepatitis C
Ottawa Hospital Research Institute|AbbVie
 July 2015 Phase 4
NCT02052349 Completed
Relative Bioavailability
AbbVie
 November 2013 Phase 1
NCT01911845 Completed
Chronic Hepatitis C Infection|Chronic Hepatitis C
AbbVie
 April 2013 Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Signaling Pathway Map